Abstracts tagged "prognostic factors"

Abstract Number: 1901 • ACR Convergence 2020
Clinical Characteristics of Importance to Outcome in Patients with Axial Spondyloarthritis: A Prospective Cohort Study
Rikke Asmussen Andreasen¹, Xenofon Baraliakos², Lars Erik Kristensen³, Kenneth Egstrup⁴, Vibeke Strand⁵, Hans Christian Horn⁶, Jimmi Wied⁶, Berit Schiøttz-Christensen⁷, Claus Aalykke¹, Inger Marie Hansen¹, Torkell Juulsgaard Ellingsen⁸ and Robin Christensen⁹, ¹Odense University Hospital, Svendborg, Svendborg, Denmark, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ³The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ⁴Odense University Hospital Svendborg, Svendborg, Denmark, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Odense University Hospital, Odense, Denmark, ⁷Spine Centre of Southern Denmark. Hospital lillebaelt, Middelfart, Denmark, ⁸Rheumatology Research Unit, Dept of Rheumatology Odense University Hospital, Odense C, Denmark, ⁹Musculoskeletal Statistics Unit, The Parker Institute/Odense University Hospital, Copenhagen F, Denmark
Background/Purpose: Despite better control of inflammation, many patients with axial spondyloarthritis (axSpA) still report pain, although they could be in remission. This suggests that in…
Abstract Number: 0015 • ACR Convergence 2020
COVID -19 Lung Inflammation – What Have We Learnt so Far ?
Sriya Gokaraju¹, Maria Darda², Vinod Vijayaraghavan Nalini Warrier³, Irina Duta³, Fiona Hayes³, Yasser Ahmed⁴ and Gouri Koduri³, ¹Southend University Hospital NHS Trust, Essex, United Kingdom, ²Southend University Hospital NHS Trust, Essex, United Kingdom, ³Southend University Hospital NHS Trust, Essex, United Kingdom, ⁴Southend University Hospital, Essex, United Kingdom
Background/Purpose: The SARS CoV-2 pandemic has inspired new interest in understanding the fundamental pathology of pneumonia and Acute Respiratory Distress Syndrome (ARDS). SARS CoV-2 in…
Abstract Number: 0766 • ACR Convergence 2020
ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort
Rodrigo Garcia Salinas¹, Alvaro Ruta¹, Santiago Ruta¹, Einer Sanchez Prado¹, Jessica Torres Chichande¹ and Sebastian Magri¹, ¹Hospital Italiano La Plata, La Plata, Argentina
Background/Purpose: Autoantibody positivity, erosions, activity level, and functional capacity were classically defined as poor prognosis. Paradoxically, many of them also predict a good response to…
Abstract Number: 1968 • ACR Convergence 2020
Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development
Elena Tchetina¹, Kseniya Glemba¹, Galina Markova¹, Maksim Makarov¹ and Aleksandr Lila¹, ¹Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Osteoarthritis (OA) is a chronic rheumatic disease, which involves pain, limited inflammation, and local destruction of the knee joint. OA pain is a major…
Abstract Number: 689 • 2019 ACR/ARP Annual Meeting
Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
Alberta Hoi ¹, Hieu Nim ², Rachel Koelmeyer ², Ying Sun ³, Amy Kao ⁴, Oliver Guenther ³ and Eric Morand², ¹School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Merck Healthcare KGaA, Darmstadt, Germany, ⁴EMD Serono Research & Development Institute, Inc., Billerica, MA
Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in…
Abstract Number: 2012 • 2019 ACR/ARP Annual Meeting
A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients
Peter Taylor¹, Bryan Downie ², Emon Elboudwarej ³, Rachael Hawtin ³, Amer M. Mirza ³ and Jinfeng Liu ³, ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster Citty, CA, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
Abstract Number: 2326 • 2019 ACR/ARP Annual Meeting
Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
Annelies Blanken¹, Rabia Agca ², Conny van der Laken ³ and Mike Nurmohamed ⁴, ¹Amsterdam Rheumatology and immunulogy Center location Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center location Amsterdam UMC location VU medical center, Amsterdam, Netherlands Antilles, ⁴Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, explained both by an increased prevalence of traditional CV risk factors and…
Abstract Number: 2625 • 2019 ACR/ARP Annual Meeting
Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement
Gelsomina Alle¹, John Jaramillo Gallego ², Marina Scolnik ³, Valeria Scaglioni ², Martin Brom ⁴, Carlos Varela ⁵, Gustavo Greloni ⁵ and Enrique Soriano ⁶, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Nephrology Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study was to evaluate the predictors of advanced chronic kidney disease (ACKD) in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis…
Abstract Number: 2913 • 2019 ACR/ARP Annual Meeting
Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
Antonio Carriero ¹, Giuseppina Abignano ², MIchelle Hutchinson ³, Karri Ballard ⁴ and Francesco Del Galdo⁵, ¹University of Leeds, Leeds, England, United Kingdom, ²3Rheumatology Institute of Lucania (IReL) and University of Leeds, Leeds, United Kingdom, ³University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, England, United Kingdom, ⁴Myriad RBM, austin, TX, ⁵University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a highly heterogeneous disease orphan of effective disease modifying agents. The diffuse cutaneous clinical subset (dcSSc) is currently targeted in…
Abstract Number: 660 • 2018 ACR/ARHP Annual Meeting
Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data
Mikhail Protopopov¹, Fabian Proft¹, Alexandre Sepriano^2,3, Robert B.M. Landewé^4,5, Désirée van der Heijde², Joachim Sieper¹, Martin Rudwaleit^6,7 and Denis Poddubnyy^1,8, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, ⁴Zuyderland Medical Center, Heerlen, Netherlands, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands, ⁶Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁷Rheumatology, Klinikum Bielefeld Rosenhöhe, Berlin, Germany, ⁸German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: It is known that radiographic progression of sacroiliitis in axial spondyloarthritis (axSpA) is quite slow, with only few predictors of such progression identified. An…
Abstract Number: 863 • 2018 ACR/ARHP Annual Meeting
Combining Cardiac Magnetic Resonance and Right Heart Catheterization to Evaluate Right Ventricular Function for the Prognosis Prediction in Patients with Connective Tissue Diseases and Pulmonary Hypertension
Nobuya Abe¹, Masaru Kato², Hiroyuki Nakamura², Atsushi Noguchi², Yuichiro Fujieda², Kenji Oku², Toshiyuki Bohgaki², Olga Amengual², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH), particularly PAH associated with systemic sclerosis (SSc-PAH), has a poor prognosis compared with other PAH.…
Abstract Number: 1502 • 2018 ACR/ARHP Annual Meeting
Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors
Xavier M Teitsma¹, Johannes W. G. Jacobs², Pascal HP de Jong³, JMW Hazes³, Angelique EAM Weel^3,4, Paco MJ Welsing¹, Attila Pethö-Schramm⁵, Michelle EA Borm⁶, Jacob van Laar¹, Johannes W. J. Bijlsma⁷ and Floris PJG Lafeber⁸, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁴Rheumatology, Maastad Hospital, Rotterdam, Netherlands, ⁵F. Hoffmann-La Roche, Basel, Switzerland, ⁶Roche Nederland BV, Woerden, Netherlands, ⁷Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁸Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: We previously identified higher disease activity score assessing 28 joints (DAS28) at baseline, current smoking and no alcohol consumption as clinical predictors for inadequate…
Abstract Number: 1718 • 2018 ACR/ARHP Annual Meeting
Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change
Chase Correia¹, Mary A. Carns², Kathleen Aren², Monique Hinchcliff³ and J. Matthew Mahoney⁴, ¹Rheumatology, Northwestern Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Rheumatology, Northwestern University, Chicago, IL, ⁴Neurological Sciences, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Systemic sclerosis (SSc) causes varying degrees of skin fibrosis with varying trajectory. Extent of skin involvement is measured by the modified Rodnan skin score…
Abstract Number: 1749 • 2018 ACR/ARHP Annual Meeting
Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Patients with pulmonary-renal or renal-limited microscopic polyangiitis (MPA) frequently manifested with rapidly progressive glomerular nephritis resulting in chronic renal failure if clinical response to…
Abstract Number: 1885 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s disease): A Multicenter Study of 224 Patients
Alexandre LE JONCOUR¹, Simon Soudet², Axelle Dupont³, Olivier Espitia⁴, Fabien Koskas⁵, Philippe Cluzel⁶, Pierre-Yves Hatron², Joseph Emmerich⁷, Patrice Cacoub¹, Matthieu Resche-Rigon³, Marc Lambert² and David Saadoun¹, ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier Pitié, Paris, France, ²Département de Médecine Interne et Immunologie Clinique, CHU Lille, F-59000 Lille, France, Centre National de Référence des Maladies Autoimmunes et Systémiques Rares (Sclérodermie), France, Lille, France, ³3Service de Biostatistique et Information médicale, Hôpital Saint-Louis, APHP, Paris, France, Paris, France, ⁴Département de Médecine interne, CHU de Nantes, France, Nantes, France, ⁵Service de chirurgie vasculaire, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Paris, France, ⁶Service d’Imagerie Cardiovasculaire, Institut de cardiologie, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Paris, France, ⁷Department of Vascular Medicine and Cardiology, University Hospital Hotel Dieu, University Paris-Descartes, Paris, France, Paris, France
Background/Purpose: Data regarding long term outcome of patients with thromboangiitis obliterans (TAO) are lacking and most series come from India and Japan. We assess long-term…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].